Blog - Surgical Mesh

Posted on April 30, 2019 by Marty Aisenberg

Last week I wrote about the FDA’s decision to ban surgical mesh for transvaginal repair of pelvic organ prolapse (POP).  The FDA took this action only after tens of thousands of lawsuits were filed to recover for injuries caused by transvaginal mesh, 4 years of heightened FDA surveillance of transvaginal mesh complications, more than 2 years that the FDA gave the manufacturers to produce sufficient evidence that the benefits of transvaginal mesh repair of POP outweigh the risks, and an additional year for the FDA to determine that the manufacturers had not produced the required evidence. 

Vident
2019 © Vident Partners.